Necrobiosis lipoidica

Global Ulcerated Necrobiosis Lipoidica Market Report to 2032 - Insights, Epidemiology and Forecasts - ResearchAndMarkets.com

Retrieved on: 
Friday, November 25, 2022
Health, Other Health, MOA, Report, United Kingdom, Necrobiosis lipoidica, III, Prevalence, SWOT, Research, II, ROA, Dietary supplement, Pharmaceutical industry, Renewable energy, Epidemiology

The "Ulcerated Necrobiosis Lipoidica - Market Insights, Epidemiology, and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Ulcerated Necrobiosis Lipoidica - Market Insights, Epidemiology, and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering.
  • This report delivers an in-depth understanding of the Ulcerated Necrobiosis Lipoidica, historical and forecasted epidemiology as well as the Ulcerated Necrobiosis Lipoidica market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
  • The Ulcerated Necrobiosis Lipoidica market report provides current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted 7MM Ulcerated Necrobiosis Lipoidica market size from 2019 to 2032.
  • What would be the Ulcerated Necrobiosis Lipoidica market growth till 2032 and what will be the resultant market size in the year 2032?

Processa Pharmaceuticals Provides Update on Enrollment Across all Clinical Programs

Retrieved on: 
Thursday, September 15, 2022
Nucleotide, Safety, Trial of the century, DPD, MTD, Disease, PTX, Gastroparesis, Gastrointestinal cancer, Company, Cardiotoxicity, GI, PCSA, NDA, COVID, Metabolism, Survival, Program, Patient, Travel, Risk, Breast cancer, Acral lentiginous melanoma, Quality of life, Nasdaq, Pentoxifylline, Constipation, Statistics, Pharmacokinetics, GLOBE, SEC, Awareness, Form 10-K, Indigestion, Cell death, Necrobiosis lipoidica, Pharmaceutical industry, Medicine, MD, Capecitabine, Processa edulis

New site added for PCS6422 to accelerate enrollment, important data on de novo formation of DPD in October.

Key Points: 
  • New site added for PCS6422 to accelerate enrollment, important data on de novo formation of DPD in October.
  • Efforts to create awareness of trials have had a positive effect on our enrollment across clinical programs.
  • HANOVER, MD, Sept. 15, 2022 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), (Processa or Company), a clinical stage biopharmaceutical company focused on developing products to improve survival and/or quality of life for patients who have an unmet medical need condition for which there are few or no therapeutic options, today provided an update on enrollment across all its clinical programs.
  • We continue to advance our clinical programs and with the expectation of important data from these programs in late 2022, each program will move further in the clinical development towards NDA submissions.

Processa Pharmaceuticals Announces Launch of Website to Increase Awareness of Ulcerative Necrobiosis Lipoidica and to Inform Patients of the ongoing Phase 2B Study of PCS499

Retrieved on: 
Thursday, August 4, 2022
People, FDA, Woman, PCSA, Survival, Risk, NL, PTX, Trial of the century, GLOBE, Necrobiosis lipoidica, SEC, Cancer, Ulcerative colitis, Patient, Quality of life, Company, Amputation, Pentoxifylline, Breast cancer, UNL, Skin, Safety, Awareness, Infection, NASDAQ, Form 10-K, Diabetes, Food and Drug Administration, Pharming, NCT, Gastroparesis, Necrosis, Food, Pharmaceutical industry, Processa edulis, MD

The website is designed to increase awareness of ulcerative Necrobiosis Lipoidica (uNL), an extremely rare condition, and to inform patients about the ongoing Phase 2 study that is investigating the use of PCS499 for the treatment of this rare condition.

Key Points: 
  • The website is designed to increase awareness of ulcerative Necrobiosis Lipoidica (uNL), an extremely rare condition, and to inform patients about the ongoing Phase 2 study that is investigating the use of PCS499 for the treatment of this rare condition.
  • Necrobiosis Lipoidica (NL) is a chronic skin condition with no currently approved U.S. Food and Drug Administration (FDA) treatment.
  • Processa Pharmaceuticals is conducting a randomized, double blind, placebo-controlled study that will evaluate the efficacy and safety of PCS499 as compared to placebo for the treatment of ulcerations of patients with Necrobiosis Lipoidica (NCT#NCT04800562).
  • Active clinical pipeline programs include: PCS6422 (metastatic colorectal cancer and breast cancer), PCS499 (ulcerative necrobiosis lipoidica) and PCS12852 (gastroparesis).

Processa Pharmaceuticals Announces Launch of Website (www.Necrobiosislipoidicastudy.com) to Increase Awareness of Ulcerative Necrobiosis Lipoidica and to Inform Patients of the ongoing Phase 2B Study of PCS499

Retrieved on: 
Wednesday, August 3, 2022
People, Necrosis, Quality of life, Ulcerative colitis, Skin, Necrobiosis lipoidica, Pharming, Woman, NCT, Trial of the century, Amputation, Risk, Patient, NASDAQ, Food, Company, Survival, Diabetes, Safety, FDA, Gastroparesis, Infection, PCSA, Form 10-K, Cancer, NL, Pentoxifylline, GLOBE, Breast cancer, Food and Drug Administration, UNL, SEC, Awareness, PTX, Pharmaceutical industry, Processa edulis, MD

The website is designed to increase awareness of ulcerative Necrobiosis Lipoidica (uNL), an extremely rare condition, and to inform patients about the ongoing Phase 2 study that is investigating the use of PCS499 for the treatment of this rare condition.

Key Points: 
  • The website is designed to increase awareness of ulcerative Necrobiosis Lipoidica (uNL), an extremely rare condition, and to inform patients about the ongoing Phase 2 study that is investigating the use of PCS499 for the treatment of this rare condition.
  • Necrobiosis Lipoidica (NL) is a chronic skin condition with no currently approved U.S. Food and Drug Administration (FDA) treatment.
  • Processa Pharmaceuticals is conducting a randomized, double blind, placebo-controlled study that will evaluate the efficacy and safety of PCS499 as compared to placebo for the treatment of ulcerations of patients with Necrobiosis Lipoidica (NCT#NCT04800562).
  • Active clinical pipeline programs include: PCS6422 (metastatic colorectal cancer and breast cancer), PCS499 (ulcerative necrobiosis lipoidica) and PCS12852 (gastroparesis).

Processa Pharmaceuticals Announces First Patient Dosed in its Randomized Double-Blind, Placebo-Controlled Clinical Trial to Evaluate PCS499 in Treating Ulcerations in Patients Who Have Necrobiosis Lipoidica

Retrieved on: 
Thursday, May 20, 2021
Digestive diseases, Medical specialties, Gastroenterology, Diabetes, Necrobiosis lipoidica, Necrobiosis, Gastroparesis, Colorectal cancer

NL is a rare, chronic, idiopathic, granulomatous disease of collagen degeneration caused by a number of very diverse pathophysiological changes in a patient.

Key Points: 
  • NL is a rare, chronic, idiopathic, granulomatous disease of collagen degeneration caused by a number of very diverse pathophysiological changes in a patient.
  • We are excited to have randomized the first patient in this Phase 2B trial.\xe2\x80\x9d\nThe Principal Investigator for the trial is Dr. Misha Rosenbach.
  • The Company uses these criteria for selection to further develop its pipeline programs to achieve high-value milestones effectively and efficiently.
  • Active clinical pipeline programs include: PCS6422 (metastatic colorectal cancer and breast cancer), PCS499 (ulcerative necrobiosis lipoidica) and PCS12852 (GI motility/gastroparesis).

Processa Announces Sites Selected for Phase 2B Clinical Trial to Treat Patients with Ulcerated Necrobiosis Lipoidica

Retrieved on: 
Wednesday, March 17, 2021
Medical specialties, Digestive diseases, Clinical medicine, Diabetes, Necrobiosis lipoidica, Necrobiosis, Cancer, Breast cancer, Gastroparesis, Ulcer, Metástasis

A summary of the study and a listing of the sites selected can be found at https://clinicaltrials.gov using the NCT number of NCT04800562.

Key Points: 
  • A summary of the study and a listing of the sites selected can be found at https://clinicaltrials.gov using the NCT number of NCT04800562.
  • Necrobiosis Lipoidica (NL) is a rare, painful condition affecting the skin and tissue under the skin typically on the lower extremities.
  • We have selected 5 US sites to evaluate this ground-breaking new treatment for ulcerative necrobiosis lipoidica and we expect to add a few more sites in the next few months including sites outside the U.S.
  • Active clinical pipeline programs include: PCS6422 (metastatic colorectal cancer and breast cancer), PCS499 (ulcerative necrobiosis lipoidica) and PCS12852 (GI motility/gastroparesis).